Food and Drug Administration (FDA) has developed a “green list” import alert aimed to stop glucagon-like peptide-1 (GLP-1) active pharmaceutical ingredients (APIs) from unverified foreign sources, which could pose safety risks, from entering the United States supply chain. The green list will record the GLP-1 APIs produced by facilities that comply with FDA’s standards. FDA notes that it will continue to monitor the market and work with state regulators to prevent unsafe GLP-1 drugs from entering the US.